Skip to main content

This is a preprint.

It has not yet been peer reviewed by a journal.

The National Library of Medicine is running a pilot to include preprints that result from research funded by NIH in PMC and PubMed.

bioRxiv logoLink to bioRxiv
[Preprint]. 2021 Oct 24:2021.10.23.465542. [Version 1] doi: 10.1101/2021.10.23.465542

Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway

Matthew Gagne, Kizzmekia S Corbett, Barbara J Flynn, Kathryn E Foulds, Danielle A Wagner, Shayne F Andrew, John-Paul M Todd, Christopher Cole Honeycutt, Lauren McCormick, Saule T Nurmukhambetova, Meredith E Davis-Gardner, Laurent Pessaint, Kevin W Bock, Bianca M Nagata, Mahnaz Minai, Anne P Werner, Juan I Moliva, Courtney Tucker, Cynthia G Lorang, Bingchun Zhao, Elizabeth McCarthy, Anthony Cook, Alan Dodson, Prakriti Mudvari, Jesmine Roberts-Torres, Farida Laboune, Lingshu Wang, Adrienne Goode, Swagata Kar, Seyhan Boyoglu-Barnum, Eun Sung Yang, Wei Shi, Aurélie Ploquin, Nicole Doria-Rose, Andrea Carfi, John R Mascola, Eli A Boritz, Darin K Edwards, Hanne Andersen, Mark G Lewis, Mehul S Suthar, Barney S Graham, Mario Roederer, Ian N Moore, Martha C Nason, Nancy J Sullivan, Daniel C Douek, Robert A Seder
PMCID: PMC8562540  PMID: 34729558

ABSTRACT

mRNA-1273 vaccine efficacy against SARS-CoV-2 Delta wanes over time; however, there are limited data on the impact of durability of immune responses on protection. We immunized rhesus macaques at weeks 0 and 4 and assessed immune responses over one year in blood, upper and lower airways. Serum neutralizing titers to Delta were 280 and 34 reciprocal ID 50 at weeks 6 (peak) and 48 (challenge), respectively. Antibody binding titers also decreased in bronchoalveolar lavage (BAL). Four days after challenge, virus was unculturable in BAL and subgenomic RNA declined ∼3-log 10 compared to control animals. In nasal swabs, sgRNA declined 1-log 10 and virus remained culturable. Anamnestic antibody responses (590-fold increase) but not T cell responses were detected in BAL by day 4 post-challenge. mRNA-1273-mediated protection in the lungs is durable but delayed and potentially dependent on anamnestic antibody responses. Rapid and sustained protection in upper and lower airways may eventually require a boost.

Full Text Availability

The license terms selected by the author(s) for this preprint version do not permit archiving in PMC. The full text is available from the preprint server.


Articles from bioRxiv are provided here courtesy of Cold Spring Harbor Laboratory Preprints

RESOURCES